Embargoed until:
Publicly released:
2024-07-30 04:00
People with diabetes who received a drug in the same group of diabetes/weight loss drugs as Ozempic – a glucagon-like peptide-1 receptor agonist (GLP-1 RA) called liraglutide –  improved key markers of heart health, according to international and Australian research. The researchers found that, compared to another type of diabetes drug, those taking liraglutide for 16 weeks improved key measures of heart health. These measures are thought to point to potential ways that heart disease develops in type 2 diabetes. The researchers say the effects of liraglutide on these measures offer important insights into how these drugs might be having beneficial effects on heart disease as well as diabetes.
Journal/conference: Journal of the American College of Cardiology
Link to research (DOI): 10.1016/j.jacc.2024.04.064
Organisation/s: Baker Heart and Diabetes Institute, Monash University, The University of Melbourne, University of Leeds, UK
Funder: This independent research has been jointly
funded by the Wellcome Trust (grant number: 221690/Z/20/Z) and
Diabetes UK (grant number:18/0005870) and has been performed at
the National Institute for Health and Care Research (NIHR) Leeds
Biomedical Research Centre (BRC) (NIHR203331). Funding for open
access charge is from Wellcome Trust (grant number: 221690/Z/20/Z).
Dr Chowdhary has received grants from the British Heart Foundation
(grant number: FS/CRTF/20/24003). Dr Valkovic has received grants
from the Sir Henry Dale Fellowship supported jointly by the Wellcome
Trust and the Royal Society (#221805/Z/20/Z), and Slovak Grant
Agencies VEGA (#2/0004/23) and APVV (#21-0299). Dr Levelt acknowledges
support from the Wellcome Trust Clinical Career Development
Fellowship (grant number: 221690/Z/20/Z), Diabetes UK
(grant number: UK 18/0005908) and the NIHR Leeds Biomedical
Research Centre.
Attachments:
Note: Not all attachments are visible to the general public
American College of Cardiology
Web page
American College of Cardiology
Web page